The biopharma industry finds itself at a crossroads in 2023. COVID-19 showed the old approaches cannot comfortably scope with disruption, but the industry is yet to settle on a new model and innovative ideas on how to prepare. 2023 is the year to sit down and collectively decide on how to move forward.
Industry collaboration has never been more important. From building more resilient supply chains to unlocking the potential of novel modalities such as adeno-associated virus (AAV), lentivirus gene therapies, mRNA therapies and vaccines: vendors and suppliers have entered a new era.
In many cases, digitalization, automation and artificial intelligence will play a role. And while regulators are still clarifying the requirements for activities such as purification for some modalities, customers and suppliers, faced with the challenges, are collaborating for mutual benefit.
